CPR Investments’s Bionano Genomics BNGO Stock Holding History

CPR Investments’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-49	Closed	-$77K	–	50
2022 Q1	$77K	Buy	49 +32	+188%	+$43.2K	0.06%	77
2021 Q4	$31K	Buy	+17	New	+$45.5K	0.02%	69

Other funds holding BNGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

CPR Investments's BNGO Position: Q2 2022 in Review

CPR Investments sold out of Bionano Genomics (BNGO) in Q2 2022, closing a stake of 49 shares — an estimated $77K sold.

CPR Investments first reported a position in BNGO in Q4 2021 and held it in 2 quarters. The position peaked at $77K in Q1 2022. 143 funds tracked by Wall St. Rank hold BNGO as of Q2 2022.

CPR Investments reported no remaining Bionano Genomics position as of Q2 2022 after selling out during the quarter.
CPR Investments sold 49 Bionano Genomics shares in Q2 2022, an estimated $77K.
CPR Investments first reported a position in Bionano Genomics in Q4 2021 and held it in 2 quarters.
CPR Investments's Bionano Genomics position peaked at $77K in Q1 2022.
143 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2022.

Based on CPR Investments's 13F filing for Q2 2022, filed 11 Aug 2022.